Evaluate the Efficacy & Safety of DWJ211 in Patient With Moderate or

Updated 06/21/2024

Status Completed

Clinical Trial Summary

Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat

Clinical Trial Description

DWJ211 is a injectable drug for improvement in the appearance of moderate to severe submental fat (SMF) ;

Study Design

Related Conditions & MeSH terms

Submental Fat

Clinical Trial Details

NCT number	NCT03946592
Study type	Interventional
Source	Daewoong Pharmaceutical Co. LTD.
Contact
Status	Completed
Phase	Phase 3
Start date	May 15, 2019
Completion date	July 2, 2020

See also
	Status	Clinical Trial	Phase
	Completed	`NCT05476679` - Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events	Phase 1/Phase 2
	Completed	`NCT04144049` - A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat	Phase 2
	Active, not recruiting	`NCT05154955` - A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat	Phase 2
	Completed	`NCT04258761` - A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")	Phase 2
	Completed	`NCT05763160` - An Open-label Study That Will Test a Second Treatment Session of RZL-012.	Phase 2
	Completed	`NCT04867434` - Efficacy and Safety of RZL-012 on Submental Fat Reduction	Phase 2
	Completed	`NCT05466448` - An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.	Phase 1/Phase 2
	Completed	`NCT04086823` - A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.	Phase 2
	Completed	`NCT02159729` - Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101	Phase 2
	Completed	`NCT05195112` - Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat	Phase 3
	Completed	`NCT03005717` - Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat	Phase 2
	Completed	`NCT02163902` - Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101	Phase 3
	Completed	`NCT05476094` - Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects	Phase 1